BAKERBOND WP PEI(CH2CH2NH) 15\um Prep HPLC Column from J.T. Baker
Anti-Ezrin / Radixin / Moesin Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-mSmac/DIABLO (CT) Polyclonal Antibody, Unconjugated from Assay Designs/Stressgen Bioreagents
Rabbit Anti-Human ADAMTS16 Polyclonal Antibody, Unconjugated from Abcam
Biology Products:(Date:11/22/2009)...ldren exposed prenatally to tobacco smoke and duri... for ADHD, according to research done at Cincinnat...y estimates that up to 35 percent of ADHD cases in...duced by eliminating both of these environmental e...children , "Tobacco and lead exposure each have...
(Date:11/22/2009)...e Life scientists have inventoried an astonishing ...species that have never known sunlight - creatures...rld down to 5,000 meters (~3 miles) below the ocea...ar and other vanguard technologies, animals known ... 17,650, a diverse collection of species ranging f...
(Date:11/22/2009).... November 18, 2009 -- A butterfly,s proboscis loo...ping -- but it works more like a paper towel, acco...He hopes to borrow the tricks of this piece of ins...he fluid inside of cells. , Kornev will present ...he American Physical Society,s (APS) Division of F...
Breaking Biology News(10 mins):Exposure to lead, tobacco smoke raises risk of ADHD 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9For gay and straight men facial attraction operates similarly 60412 1For gay and straight men facial attraction operates similarly 60412 2ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 1ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 2ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 3Inconspicuous leaf beetles reveal environments role in formation of new species 10590 1Inconspicuous leaf beetles reveal environments role in formation of new species 10590 2Inconspicuous leaf beetles reveal environments role in formation of new species 10590 3(Date:11/19/2009)...19 Omeros Corporation (N... results for the third quarter ended September 30,...09, Omeros reported a net loss of $3.9 million, or...4 million, or $2.54 per share, for the same period...2009, the Company reported a net loss of $15.5 mil...
(Date:11/19/2009)...THESDA, Md., Nov. 19 Sph...n biotechnology for diabetes therapy, and a provid... to food, supplement, biotechnology and pharmaceut...iously reported $6.3 million registered direct pla...res of its common stock and warrants to purchase u...
(Date:11/19/2009)... Nov. 19 Spherix Incorpo...ogy for diabetes therapy, and a provider of techni...pplement, biotechnology and pharmaceutical compani...l Meeting of Shareholders. ,, At the meeting, s... ) elected the following members to the Board of D...
(Date:11/19/2009)..., Germany, November 19 MONITORING ...ber 16th, 2009 Flibanserin in the,indication treat...nson,s,disease for orphan drug status designation ...a-induced dyskinesia is a complication of the main...us burden to some of those,affected, since it may ...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2